Trust Size
$4M
Peak Price
$1054.50
Current Price
$5.55
Return
-44.5%
Price Journey
What Happened
Tevogen Bio is a clinical-stage biopharmaceutical company developing T-cell therapies for infectious diseases and cancer using its proprietary ExacTcell platform.
Tevogen Bio went public through a SPAC merger and trades under TVGN. The company's ExacTcell platform produces precise T-cell therapies that can be manufactured and stored as off-the-shelf treatments. The company has attracted attention for its approach to T-cell therapy but remains early-stage with limited clinical data.
Timeline
2021-10-22
S-1 Registration Filed
🔀 Reverse Stock Split
Reverse split ratio: . Reverse splits are used to avoid delisting but destroy shareholder value through the illusion of a higher stock price.
SEC Filing Details
CIK Number
1860871
Total SEC Filings
269
State of Incorporation
DE
Last Filing Date
2026-03-17
Business Location
New York, NY
Trust/Asset Size
$4M
Data sourced from SEC EDGAR Company Facts API and EFTS search index.
📄 SEC Filings
View all EDGAR filings for Tevogen Bio Holdings